Read More Pharma Industry News Soligenix announces promising results in extended HyBryte treatment study for cutaneous T-cell lymphoma Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company, has shared an interim update on a key study involving… byPallavi MadhirajuJuly 10, 2024